AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23456136 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculoskeletal ultrasound (M-US) measurements of muscle thickness, pennation angle, and echogenicity of musculus quadriceps
Number of subjects: 52
Study 23456136 — intervention group
Group type: EXPERIMENTAL
Intervention: Thickness of musculus vastus medialis measured by M-US
Number of subjects: 52
Study 23456136 — intervention group
Group type: EXPERIMENTAL
Intervention: M-US measurements of muscle thickness
Number of subjects: 52
Study 21299401 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days of continuous glucose monitoring
Number of subjects: 185
Study 21299401 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 days of continuous glucose monitoring
Number of subjects: 185
Study 21299401 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-15 days of monitoring every 3 months
Number of subjects: 185
Study 19896062 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia head
Number of subjects: 62
Study 19896062 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-chromium head
Number of subjects: 62
Study 16741302 — intervention group
Group type: EXPERIMENTAL
Intervention: (11)C‐choline PET
Number of subjects: 27
Study 16741302 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced CT
Number of subjects: 27
Study 16741302 — intervention group
Group type: COMPARATOR
Intervention: Both modalities
Number of subjects: 27
Study 15635998 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest compression (HFCC)
Number of subjects: 12
Study 15635998 — intervention group
Group type: COMPARATOR
Intervention: Standard chest physical therapy (CPT)
Number of subjects: 12
Study 11760478 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-MCT/LCT
Number of subjects: 184
Study 11760478 — intervention group
Group type: COMPARATOR
Intervention: Propofol-LCT
Number of subjects: 184
Study 9433788 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 2
Study 9433788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 8353361 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 16.5 g of fish oil in 1500 ml (Impact)
Number of subjects: 16
Study 8353361 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard enteral formulas devoid of fish oil)
Number of subjects: 16
Study 3071872 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal endoscopic microsurgery
Number of subjects: 140
Study 3071872 — intervention group
Group type: EXPERIMENTAL
Intervention: Local surgery alone for pT1 carcinoma
Number of subjects: 140
Study 31010445 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (flexible doses of 10/20 mg)
Number of subjects: 0
Study 31010445 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram (flexible doses of 10/20 mg)
Number of subjects: 0
Study 30239857 — intervention group
Group type: EXPERIMENTAL
Intervention: nIPPV
Number of subjects: 84
Study 30239857 — intervention group
Group type: COMPARATOR
Intervention: nCPAP
Number of subjects: 84
Study 28829518 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM)
Number of subjects: 35
Study 28829518 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 35
Study 25344794 — intervention group
Group type: EXPERIMENTAL
Intervention: VocSyl
Number of subjects: 18
Study 25344794 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing Board
Number of subjects: 18
Study 25344794 — intervention group
Group type: COMPARATOR
Intervention: Active Control Group
Number of subjects: 18
Study 24321337 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Fit Plus (12 weeks)
Number of subjects: 220
Study 24321337 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care for 12 weeks, then Wii Fit Plus)
Number of subjects: 220
Study 21217529 — intervention group
Group type: EXPERIMENTAL
Intervention: CKCE (sling-based exercises)
Number of subjects: 26
Study 21217529 — intervention group
Group type: COMPARATOR
Intervention: OKCE (traditional exercises)
Number of subjects: 26
Study 21217529 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CKCE and OKCE
Number of subjects: 26
Study 21217529 — intervention group
Group type: EXPERIMENTAL
Intervention: CKCE and OKCE
Number of subjects: 26
Study 19820745 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching critical appraisal skills in dental schools
Number of subjects: 0
Study 21586199 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 17
Study 21586199 — intervention group
Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 17
Study 15621485 — intervention group
Group type: EXPERIMENTAL
Intervention: Small calibre (19F), flexible, fluted spiral drains with round cross-section (group A)
Number of subjects: 100
Study 15621485 — intervention group
Group type: COMPARATOR
Intervention: Standard chest drains (group B)
Number of subjects: 100
Study 11810082 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol/desogestrel
Number of subjects: 35
Study 11810082 — intervention group
Group type: COMPARATOR
Intervention: ethinyl estradiol/levonorgestrel
Number of subjects: 35
Study 9666171 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin cream
Number of subjects: 0
Study 9666171 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 0
Study 7666013 — intervention group
Group type: EXPERIMENTAL
Intervention: PHFO-diet
Number of subjects: 31
Study 7666013 — intervention group
Group type: EXPERIMENTAL
Intervention: PHSO-diet
Number of subjects: 31
Study 7666013 — intervention group
Group type: COMPARATOR
Intervention: butter-diet
Number of subjects: 31
Study 2669154 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 gm of intravenous cefotetan after forceps delivery
Number of subjects: 393
Study 2669154 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 393
Study 301428 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunized groups
Number of subjects: 55
Study 301428 — intervention group
Group type: COMPARATOR
Intervention: Nonimmunized groups
Number of subjects: 55
Study 11098941 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid pulse check during pulsatile (spontaneous) circulation
Number of subjects: 206
Study 11098941 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid pulse check during nonpulsatile (extracorporeal) circulation
Number of subjects: 206
Study 11098941 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced training level
Number of subjects: 206
Study 11098941 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic cardiopulmonary resuscitation training
Number of subjects: 206
Study 31688452 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine 40 mg/d
Number of subjects: 152
Study 31688452 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine 80 mg/d
Number of subjects: 152
Study 30138014 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral therapy (ICBT)
Number of subjects: 165
Study 30138014 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (GCBT)
Number of subjects: 165
Study 30138014 — intervention group
Group type: COMPARATOR
Intervention: Wait list (WL)
Number of subjects: 165
Study 30138014 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (GCBT) for children diagnosed with social anxiety disorder (SOC)
Number of subjects: 165
Study 26888149 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban (60 mg)
Number of subjects: 1943
Study 26888149 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose edoxaban (30 mg)
Number of subjects: 1943
Study 26888149 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1943
Study 25251294 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate (DARK)
Number of subjects: 25
Study 25251294 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat β‐glucan and dark chocolate (B‐GLU + DARK)
Number of subjects: 25
Study 25251294 — intervention group
Group type: COMPARATOR
Intervention: Milk chocolate (CON)
Number of subjects: 25
Study 21585523 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftazone (titrated up to 120 mg/day)
Number of subjects: 7
Study 21067351 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated trivalent seasonal influenza vaccine (TIV)
Number of subjects: 119
Study 21067351 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 119
Study 21067351 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal influenza A infection
Number of subjects: 119
Study 21067351 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal TIV
Number of subjects: 119
Study 17996568 — intervention group
Group type: EXPERIMENTAL
Intervention: F-18-fluorodeoxyglucose (FDG) PET-assisted management
Number of subjects: 430
Study 17996568 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 430
Study 17996568 — intervention group
Group type: EXPERIMENTAL
Intervention: F-18-fluorodeoxyglucose (FDG) PET-assisted management (adhered to recommendations)
Number of subjects: 430
Study 17996568 — intervention group
Group type: EXPERIMENTAL
Intervention: F-18-fluorodeoxyglucose (FDG) PET-assisted management (without recent angiography)
Number of subjects: 430
Study 14962151 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 37.5 mg/acetaminophen 325 mg combination tablets (tramadol/APAP)
Number of subjects: 113
Study 14962151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 11668378 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic venous insufficiency patients (group I)
Number of subjects: 9
Study 11668378 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (group II)
Number of subjects: 9
Study 11668378 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 9
Study 9689909 — intervention group
Group type: EXPERIMENTAL
Intervention: List composition (common vs. unusual verbal information)
Number of subjects: 0
Study 9689909 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid model incorporating intralist and extralist sources of distinctiveness and expectation-violating mechanism
Number of subjects: 0
Study 8130041 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% 1 ml kg-1 + Clonidine 2 micrograms kg-1 in normal saline 1 ml (Group B)
Number of subjects: 46
Study 8130041 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25% 1 ml kg-1 + Normal saline 1 ml (Group A)
Number of subjects: 46
Study 2573228 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 22
Study 2573228 — intervention group
Group type: COMPARATOR
Intervention: Systemic opioids
Number of subjects: 22
Study 1104655 — intervention group
Group type: EXPERIMENTAL
Intervention: Live, attenuated, influenza type A (H3N2) vaccine (Alice)
Number of subjects: 95
Study 1104655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 30064455 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid together with 10 × 106 cultured autologous bone marrow-derived MSCs (Low-dose)
Number of subjects: 30
Study 30064455 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid together with 100 × 106 cultured autologous bone marrow-derived MSCs (High-dose)
Number of subjects: 30
Study 30064455 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid alone (Control)
Number of subjects: 30
Study 28801071 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation Therapy (SMT)
Number of subjects: 92
Study 28801071 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Mobilization (MOB)
Number of subjects: 92
Study 28801071 — intervention group
Group type: COMPARATOR
Intervention: No Treatment (REST)
Number of subjects: 92
Study 28801071 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of TSP clusters
Number of subjects: 92
Study 25148887 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion (BPD)
Number of subjects: 31
Study 25148887 — intervention group
Group type: COMPARATOR
Intervention: Lean-control group
Number of subjects: 31
Study 25148887 — intervention group
Group type: COMPARATOR
Intervention: Obese-control group
Number of subjects: 31
Study 23075062 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed lingual appliances (Stealth®, AO, Sheboygan, Wisc)
Number of subjects: 34
Study 23075062 — intervention group
Group type: COMPARATOR
Intervention: Conventional fixed labial appliances
Number of subjects: 34
Study 21349184 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based psychological intervention
Number of subjects: 0
Study 21349184 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 18469276 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with oat and wheat bread and potato (high postprandial insulin response)
Number of subjects: 47
Study 18469276 — intervention group
Group type: COMPARATOR
Intervention: Diet with rye bread and pasta (low postprandial insulin response)
Number of subjects: 47
Study 16563975 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus 1.5 mg twice daily (n = 101)
Number of subjects: 213
Study 16563975 — intervention group
Group type: COMPARATOR
Intervention: azathioprine 1 to 3 mg/kg/day (n = 112)
Number of subjects: 213
Study 12112884 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheath introducer with hydrophilic coating
Number of subjects: 73
Study 12112884 — intervention group
Group type: COMPARATOR
Intervention: Sheath introducer without hydrophilic coating
Number of subjects: 73
Study 10349694 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with ribavirin and rIFN-alpha 2b
Number of subjects: 2089
Study 10349694 — intervention group
Group type: COMPARATOR
Intervention: rIFN-alpha 2b alone
Number of subjects: 2089
Study 7717480 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg.kg‐1 by intramuscular injection as premedication
Number of subjects: 83
Study 7717480 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil-nitrous oxide anaesthesia without midazolam premedication (previous study)
Number of subjects: 83
Study 2149533 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 1% cream (38 patients)
Number of subjects: 75
Study 2149533 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 1% emulgel (37 patients)
Number of subjects: 75
Study 7361826 — intervention group
Group type: EXPERIMENTAL
Intervention: Independence training
Number of subjects: 75
Study 7361826 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 75
Study 7361826 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 75
Study 31433893 — intervention group
Group type: COMPARATOR
Intervention: Patient-Controlled Analgesia (PCA)
Number of subjects: 89
Study 31433893 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratus Anterior Plane Block (SAPB)
Number of subjects: 89
Study 29789868 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated rhinoplasty result
Number of subjects: 40
Study 29789868 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual rhinoplasty result
Number of subjects: 40
Study 29789868 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal tip projection
Number of subjects: 40
Study 29789868 — intervention group
Group type: COMPARATOR
Intervention: Nasal tip rotation
Number of subjects: 40
Study 28818053 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted self-interviews (CASI)
Number of subjects: 504
Study 28818053 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-CASI
Number of subjects: 504
Study 28818053 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-interview methods (CASI and audio-CASI)
Number of subjects: 504
Study 28818053 — intervention group
Group type: COMPARATOR
Intervention: Interviewer-led interviews (CAPI)
Number of subjects: 504
Study 28818053 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pen-interview
Number of subjects: 504
Study 25935875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor treatment
Number of subjects: 4990
Study 24156396 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIC Wheels program
Number of subjects: 40
Study 24156396 — intervention group
Group type: COMPARATOR
Intervention: Computer-game control group
Number of subjects: 40
Study 21127303 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 99
Study 21127303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 21127303 — intervention group
Group type: COMPARATOR
Intervention: Alteplase vs Placebo
Number of subjects: 99
Study 18495880 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (opioid antagonist)
Number of subjects: 0
Study 18495880 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 16790053 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured welfare rights assessment followed by active assistance with welfare benefit claims over 24 months.
Number of subjects: 126
Study 16790053 — intervention group
Group type: COMPARATOR
Intervention: Control group received the intervention after a six month delay.
Number of subjects: 126
Study 12663565 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of sucrose intake
Number of subjects: 39345
Study 12663565 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of fructose intake
Number of subjects: 39345
Study 12663565 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of glucose intake
Number of subjects: 39345
Study 12663565 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of lactose intake
Number of subjects: 39345
Study 11115000 — intervention group
Group type: EXPERIMENTAL
Intervention: Short hospital postnatal stay (6-48 hours)
Number of subjects: 0
Study 11115000 — intervention group
Group type: COMPARATOR
Intervention: Longer hospital postnatal stay (more than 48 hours)
Number of subjects: 0
Study 9124664 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow at levels of 0.2-3 l.min-1
Number of subjects: 12
Study 9124664 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing tidal volume at a constant respiratory rate of 15 breath.min-1
Number of subjects: 12
Study 7957519 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. iopromide 15 g iodine
Number of subjects: 12
Study 7957519 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. iopromide 80 g iodine
Number of subjects: 12
Study 7957519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3474214 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen
Number of subjects: 0
Study 3474214 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 0
Study 28229575 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume plyometric training (PLYO)
Number of subjects: 29
Study 28229575 — intervention group
Group type: COMPARATOR
Intervention: Regular training sessions (CON)
Number of subjects: 29
Study 27840340 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise, supervised 2 days per week for 10 weeks
Number of subjects: 60
Study 27840340 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerobic exercise)
Number of subjects: 60
Study 25439040 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopathic treatment (usually paracetamol, 33.5%) and homeopathic treatment (Oscillococcinum, 56.6%)
Number of subjects: 573
Study 25439040 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopathic treatment
Number of subjects: 573
Study 25439040 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 573
Study 22794202 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 60
Study 22794202 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:80,000 epinephrine
Number of subjects: 60
Study 20018316 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating voltage treatment strategy (500 shocks at 14k V, 1,000 at 16 kV, and 1,000 at 18 kV)
Number of subjects: 45
Study 20018316 — intervention group
Group type: COMPARATOR
Intervention: Fixed voltage treatment strategy (2,500 shocks at 18 kV)
Number of subjects: 45
Study 20018316 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating voltage treatment strategy
Number of subjects: 45
Study 20018316 — intervention group
Group type: COMPARATOR
Intervention: Fixed voltage treatment strategy
Number of subjects: 45
Study 18388897 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise program (10 consecutive days of treadmill walking for 1 h/day at 70‐75% of peak aerobic capacity)
Number of subjects: 31
Study 18388897 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise program
Number of subjects: 31
Study 16864174 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline containing chemotherapy
Number of subjects: 85
Study 12356187 — intervention group
Group type: COMPARATOR
Intervention: Chronic hemodialysis patients
Number of subjects: 18
Study 12356187 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis procedure
Number of subjects: 18
Study 12356187 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible and bioincompatible membranes
Number of subjects: 18
Study 12356187 — intervention group
Group type: EXPERIMENTAL
Intervention: Predialysis F2-isoprostane
Number of subjects: 18
Study 9661609 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) at an initial dose of 50 mg daily for 5 days, increased to 100 and 150 mg daily in subsequent cycles if no response was observed.
Number of subjects: 201
Study 9661609 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) treatment
Number of subjects: 201
Study 7655768 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxil (Hikma Pharmaceuticals, 750 mg)
Number of subjects: 26
Study 7655768 — intervention group
Group type: COMPARATOR
Intervention: Zinacef (Glaxo, 750 mg)
Number of subjects: 26
Study 2667318 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrons alone
Number of subjects: 49
Study 2667318 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-beam therapy
Number of subjects: 49
Study 2667318 — intervention group
Group type: COMPARATOR
Intervention: Photons
Number of subjects: 49
Study 766895 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (1 unit given intravenously)
Number of subjects: 7
Study 7016781 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY g 5421 (100 mg three times per day)
Number of subjects: 6